CALIX LIMITED (CXL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CXL

CXL - CALIX LIMITED

Year End: June
GICS Industry Group : Materials
Debt/EBITDA: -0.08
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.83

04 Mar
2026

0.010

OPEN

$0.80

1.22%

HIGH

$0.88

1,072,738

LOW

$0.77

OTHER COMPANIES IN THE SAME SECTOR
3DA . ALQ . AVD . BOL . BSA . BWN . CG1 . CLG . CVL . CWY . DOW . DUR . EGL . FLC . IPG . LBL . MAD . PPK . RWL . SDV . SHA . SND . SSM . SYL . VBC . VEE . VNT . VYS .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-9.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx28.2 M
Book Value Per Share xxxxxxxxxxxxxxx41.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-28.7 M
Net Profit Margin xxxxxxxxxxxxxxx-68.05 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-22.28 %
Return on Invested Capital xxxxxxxxxxxxxxx-21.86 %
Return on Assets xxxxxxxxxxxxxxx-17.21 %
Return on Equity xxxxxxxxxxxxxxx-22.28 %
Return on Total Capital xxxxxxxxxxxxxxx-45.40 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-39.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx23 M
Price To Book Value xxxxxxxxxxxxxxx0.83

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx10.9 M
Capex % of Sales xxxxxxxxxxxxxxx38.76 %
Cost of Goods Sold xxxxxxxxxxxxxxx29 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx40 M
Research & Development xxxxxxxxxxxxxxx18 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Shaw and Partners

25/02/2026

1

Buy

$1.70

104.82%

Shaw and Partners highlight 1H26 revenue growth of 20.7% for Calix, 5.6% ahead of the broker's estimate.

Gross profit increased by 37.5% to $6.7m on a 40% margin. Operating cash outflow narrowed -65% to -$6.2m and operating costs fell -30%, highlights the analyst.

The broker points to progress on the capital-light strategy, including a binding term sheet with PLS Group ((PLS)) that removes further funding requirements and releases $11.4m in capital.

Shaw notes multiple commercial milestones, including new US contracts and ARENA grant support, underpinning medium-term revenue growth.

Buy rating and $1.70 target are maintained.

FORECAST
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -8.40 cents.
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -5.20 cents.

CXL STOCK CHART